Immunophenotyping and Efficacy of Low Dose ATG in Non-Sensitized Kidney Recipients Undergoing Early Steroid Withdrawal: A Randomized Pilot Study by Grafals, Monica et al.
 
Immunophenotyping and Efficacy of Low Dose ATG in Non-
Sensitized Kidney Recipients Undergoing Early Steroid Withdrawal:
A Randomized Pilot Study
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Grafals, M., B. Smith, N. Murakami, A. Trabucco, K. Hamill, E.
Marangos, H. Gilligan, et al. 2014. “Immunophenotyping and
Efficacy of Low Dose ATG in Non-Sensitized Kidney Recipients
Undergoing Early Steroid Withdrawal: A Randomized Pilot
Study.” PLoS ONE 9 (8): e104408.
doi:10.1371/journal.pone.0104408.
http://dx.doi.org/10.1371/journal.pone.0104408.
Published Version doi:10.1371/journal.pone.0104408
Accessed February 16, 2015 8:38:57 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12785879
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAImmunophenotyping and Efficacy of Low Dose ATG in
Non-Sensitized Kidney Recipients Undergoing Early
Steroid Withdrawal: A Randomized Pilot Study
Monica Grafals
1,2, Brian Smith
3, Naoka Murakami
4, Agnes Trabucco
1, Katherine Hamill
1,
Erick Marangos
1, Hannah Gilligan
1, Elizabeth A. Pomfret
1, James J. Pomposelli
1, Mary A. Simpson
1,
Jamil Azzi
3, Nader Najafian
3,5, Leonardo V. Riella
3*
1Department of Transplant Surgery, Lahey Clinic Medical Center, Burlington, Massachusetts, United States of America, 2Department of Medicine, Georgetown University,
Washington, D.C., United States of America, 3Transplantation Research Center, Renal Division, Brigham & Women’s Hospital, Harvard Medical School, Boston,
Massachusetts, United States of America, 4Department of Medicine, Beth Israel Medical Center, New York, New York, United States of America, 5Department of
Nephrology, Cleveland Clinic Florida, Weston, Florida, United States of America
Abstract
Rabbit antithymocyte globulin (ATG) is commonly used as an induction therapy in renal transplant recipients, but the ideal
dosage in tacrolimus-based early steroid withdrawal protocols has not been established. The purpose of this pilot study was
to determine the immunophenotyping and efficacy of lower dose ATG in low immunological-risk kidney transplant
recipients. In this prospective study, 45 patients were randomized (1:1) to our standard dose ATG (total dose 3.75 mg/
kg)(sATG) vs. lower dose 2.25 mg/kg (lowATG). All patients underwent early steroid withdrawal within 7 days. The primary
end point was biopsy-proven acute rejection at 12 months. Prospective immunophenotyping of freshly isolated PBMCs was
performed at baseline, 3, 6, 12 months post-transplant. The rate of acute rejection was 17% and 10% in the sATG and
lowATG, respectively. Effector memory T cells, Tregs and recent thymic emigrants T cells had similar kinetics post-transplant
in both groups. No statistically significant differences were found in graft survival, patient survival or infections between the
two groups, though there was a non-significant increase in leukopenia (43%v s. 30%), CMV (8% vs. 0) and BK (4% vs. 0)
infections in sATG group vs. lowATG. In sum, in low immunological risk kidney recipients undergoing steroid withdrawal,
low dose ATG seems to be efficacious in preventing acute rejection and depleting T cells with potentially lower infectious
complications. A larger study is warranted to confirm these findings.
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Introduction
Most kidney transplant centers in the United States utilize
induction agents as part of their immunosupression protocols as it
is believed that these agents prevent early acute rejection episodes
and possibly improve graft survival [1–3]. Rabbit antithymocyte
globulin (ATG or Thymoglobulin) is the most common induction
agent used in renal transplantation and is used in more than 55%
of kidney transplants in the USA, despite not being FDA-approved
for this use [2]. ATG causes T-cell depletion by inducing
complement-dependent cell lysis. It also modulates cell surface
and adhesion molecules that regulate T-cell function and
leukocyte endothelial interactions, respectively [1,4,5]. Induction
therapy with ATG results in a lower acute rejection rate, but is also
associated with a higher risk of infections and malignancies [6–8].
An ATG dosage of 6–10 mg/kg has traditionally been the
standard of care in most transplant centers in the USA [5,9–12].
ATG has been widely studied in the cyclosporine and low-dose
steroid maintenance era, however the optimal dosage of ATG in
the setting of tacrolimus use and steroid withdrawal has not been
determined.
Our transplant center utilizes 3.75 mg/kg of ATG as induction
in both deceased and living donor renal transplantation. Because
of drug acquisition costs, risks of malignancies and infections, it is
imperative to find the minimum effective dose of ATG that still
allows for minimization of maintenance immunosupression.
Moreover, the expansion of steroid withdrawal regimens urges a
reassessment of optimal ATG dosage. Our hypothesis is that lower
ATG dose is effective and safe in non-sensitized renal transplant
recipients undergoing steroid withdrawal. Herein, we report an
open-label, single-center prospective randomized pilot study
comparing two lower dosage ATG regimens (3.75 mg/kg vs.
2.25 mg/kg) in low immunological risk recipients who underwent
steroid withdrawal and maintenance immunosuppression with
tacrolimus and mycophenolate mofetil.
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Study design and patient selection
This is a prospective, open-label, single center randomized pilot
study in adult renal transplant recipients at Lahey Clinic Medical
Center, Burlington, MA. Patients above 18 years of age who were
scheduled for a living or deceased donor renal transplant were
eligible for enrollment. Exclusion criteria included a multi-organ
transplant; a current or historic panel reactive antibody .20%;
presence of donor specific anti-HLA antibodies; and contraindi-
cation to ATG use. The recruitment time was pre-established for 2
years with one additional year of follow-up. The protocol for this
trial and supporting CONSORT checklist are available as
supporting information (see Checklist S1 and Protocol S1).
Ethics statement
The study protocol was reviewed and approved by an
Institutional Review Board at Lahey Clinic Medical Center and
was conducted in full conformance with the principles of the
Declaration of Helsinki. All study participants provided signed
informed consent previous to randomization. The study is listed on
http://clinicaltrials.gov (NCT01280617).
Randomization and treatment
After the screening process, eligible patients were randomized in
a 1:1 ratio either to receive standard dose ATG of 1.25 mg/kg63
doses (3.75 mg/kg total dose) [sATG] or low dose ATG of
0.75 mg/kg63 doses (2.25 mg/kg total dose) [lowATG] (Fig-
ure 1). For obese patients, the maximum weight used in the dose
calculation was 100 kg. After patient enrollment by a transplant
nephrologist, computer-generated protocols were utilized for
randomization (performed by research coordinator and imple-
mented by transplant nephrologist).
Patients on both arm received ATG intraoperatively on day 1,
followed by daily administration of ATG on days 2 and 3, at the
dosage according to the assignment.
All patients received maintenance immunosuppression with
tacrolimus, mycophenolate mofetil (MMF) and a 7-day cortico-
steroid taper. Tacrolimus was initiated on day 1 at 2 mg twice a
day and target blood concentrations were 8–10 ng/ml for the first
6 months post-transplant. MMF was dosed as 1000 mg twice a
day in both groups. Methylprednisolone was given intravenously
at 500 mg on day 0, 200 mg on day 1 and 100 mg on day 2.
Prednisone 20 mg was given by mouth on day 3 and 10 mg was
given on day 4, followed by fast taper. No further corticosteroid
use was planned after the first post-operative week unless patients
were on long-term prednisone prior to transplantation for other
reasons.
All patients received trimethoprim 80 mg-sulfamethoxazole
400 mg administered orally daily for six months for bacterial
and Pneumocystis jiroveci prophylaxis. Inhaled pentamidine
monthly for 6 months was given in patients allergic to sulfa
products. Valganciclovir 450 mg daily or adjusted dose for renal
function was given for cytomegalovirus (CMV) prophylaxis for
three months in low-to-intermediate risk patients (seropositive
donor and recipient [D+/R+], seronegative donor and recipient
[D2/R2] and seronegative donor and seropositive recipient
[D2/R+] and for 6 months in high-risk seropositive donor and
seronegative recipient [D+/R2] patients.
Endpoints
The primary endpoint was the incidence of biopsy-proven acute
rejection (BPAR) at 12 months post-transplant. This was
determined by pathological evidence of rejection defined by the
Banff ‘97 criteria. Delayed graft function was defined as the need
for dialysis within seven days after transplantation. Leukopenia
was defined as a WBC count of 3,500 cells/mm
3 or less.
Secondary endpoints included: patient survival, graft survival
and function (serum creatinine at 3, 6, 12 month), incidence of
infection, leukopenia (defined as WBC,3,500) and cancers.
Peripheral blood mononuclear cells (PBMC) isolation
Peripheral blood samples were obtained from patients pre-
transplantation, at 3, 6 and 12 months post-transplant. Samples
were all collected between 7–9am and were processed within
4 hours at the Immunological Core Facility at the Transplant
Research Center, Brigham and Women’s Hospital. PBMCs were
isolated by density gradient centrifugation using Ficoll-Paque
solution (GE Healthcare Biosciences) spun at 800 g for 30 minutes
at 20uC.
Flow cytometric analysis
Freshly prepared PBMCs were used for flow cytometric analysis
using four-color flow cytometry on a FACS Calibur analyzer
(Becton Dickinson, NJ) with cell surface staining using anti-
CD45RO-FITC, anti-CD31-FITC, anti-CD25-PE, anti CD4-
PerCP, anti-CD4-APC, anti-CD8-PerCP, anti-CD62L-APC, anti-
CD45RA-APC (BD Biosciences, San Jose, CA, USA). For
intracellular staining of FoxP3, permeabilization solution
(eBioscience, San Diego, CA, USA) and anti-Foxp3-FITC
(eBioscience, San Diego, CA, USA) were used based on
manufacturer’s protocol.
Statistical analysis
For this pilot study, we estimated that 40 participants in total
were needed [13]. Statistical analysis was performed in GraphPad
Prism version 5.0d and Microsoft Excel 2011. Continuous
variables were analyzed using two-tailed t tests if normally
distributed, while nonparametric Mann-Whitney test was used if
variable was not normally distributed. Categorical variables were
analyzed using chi-square testing, unless expected frequencies
were less than five in any group, in which case Fisher’s exact test
was used. We report means 6 SDs. P-values less than 0.05 were
considered significant. With the exception of patient survival, all
clinical outcomes were censored (patients not followed) beyond the
date of graft failure. Thus, analysis of renal function (serum
creatinine and eGFR) at various times post-transplant were based
on comparing patients who were still alive with functioning grafts
at those times.
Results
Study Patients
From the initiation of trial recruitment in November 2010 until
the completion of recruitment in April 2013, seventy patients were
assessed for eligibility for the study and forty-five patients
underwent randomization (Figure 1). Data collection continued
until August 2013 with a mean follow-up of 15 months. The two
arms were well balanced with no major differences in terms of
living versus deceased donor transplant, recipient’s gender, age,
ethnicity, re-transplant, diabetes, CKD etiology, dialysis time prior
to transplant, panel reactive antibody (PRA), donor age and
kidney weight (Table 1), with the exception of a slightly higher
prevalence of coronary artery disease in the lowATG group
compared with sATG (n=9 vs 4, p=0.06).
Low Dose ATG in Renal Transplant Recipients
PLOS ONE | www.plosone.org 2 August 2014 | Volume 9 | Issue 8 | e104408Outcomes
The two arms showed no significant difference at the primary
endpoint of biopsy-proven acute rejection (BPAR). The rate of
acute rejection in the lowATG group was 10% compared to 17%
in the sATG group (p=0.66) (Table 2). Patient survival at 1 year
in the lowATG group was 85% compared with 100% in the sATG
(p=0.11) (Table 2). There were two patient deaths in the lowATG
group related to cardiovascular events with a functioning graft.
Both patients had been on hemodialysis for more than five years
prior to transplantation, had history of coronary artery disease and
diabetes, and were long-term smokers. The etiology of the third
death was undetermined. Delayed graft function occurred in 40%
of patients in the lowATG group compared with 14.3% in the
sATG group (p=0.05). Serum creatinine (sCr) and eGFR were
similar between both groups at 1, 6 and 12 months post-transplant
(Figure 2). At 12 months post-transplant, the serum creatinine in
the lowATG was 1.460.44 mg/dl compared with 1.3360.0.36 in
the sATG group (p=0.56). There were no primary graft failures
on either group. There was no significant difference in the
tacrolimus trough levels and mycophenolate dosing between the
two groups (Table 2).
Adverse events
We observed more leukopenia in the sATG group compared
with the lowATG group (43% vs. 30%, p=0.34) (Table 2). There
were two cases of CMV infection in the sATG group and one of
these patients also developed BK infection. There were no cases of
either BK or CMV in the lowATG group. The incidence of severe
infection requiring hospital admission was 13% in the sATG
group compared to 10% in the lowATG group (p=0.55). There
was one case of squamous cell cancer on each group and one of
prostate cancer in the lowATG group. There was no case of post-
transplant lymphoproliferative disorder, Kaposi sarcoma or renal
cell carcinoma.
Effects of ATG on peripheral T cells
We compared the kinetics of peripheral blood T cell subsets at
baseline and at 3, 6 and 12 months post-transplant between groups
(Figure 3, 4). While CD8 T cells were recovered close to baseline
after 3 months on both groups, CD4 T cells were persistently
lower in both groups up to 12 months post-transplant (2067.1%
lowATG vs. 1763.6% high ATG compared to baseline 3563.6%
and 3765.5%, respectively) (Figure 3B). Overall, the percentage
of effector memory T cells (CD45RO+CD62Llow) was reduced at
3 months after transplantation but increased after that, reaching its
highest percentage at 12 months (Figure 3C). Tregs’ percentage
slightly increased post-transplant in both groups, though the
standard deviations were wide and differences non-significant
(Figure 4B).
The ratio of Treg/CD4effmem percentage has been suggested
to indicate immune regulation and potentially less risk of rejection
[14–16]. We observed a trend towards higher Treg/CD4effmem
at 3 months after transplant in the lowATG group, however ratio
was similar to baseline at subsequent time points (Figure 4C). We
could not identify an association between lower ratio of Treg/
CD4effmem and later rejection (data not shown). Recent thymic
emigrants (RTE) are a subset of T cells that proliferate in response
to IL-7 and in the absence of other costimulation, a property that
Figure 1. Flow diagram of patients screened and enrolled in the study.
doi:10.1371/journal.pone.0104408.g001
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ATG [17]. These cells are characterized by the expression of CD4,
CD31 and CD45RA. We assessed the kinetics of RTEs after T cell
depletion; the percentage of RTEs significantly decreased after
ATG on both groups and did not recover back to baseline after
that (Figure 4D, E). We did not observe any correlation between
the percentage of RTE and the development of leukopenia after
ATG.
Cost minimization
Though beyond the scope of this paper, the cost-effectiveness of
the different strategies was assessed. ATG costs $600 per 25 mg
vial. On an average 80 kg representative patient, the standard
dose ATG recipient (3.75 mg/kg total) received 100 mg63 doses
(12 vials), which equals $7,200, while the lowATG recipient
(2.25 mg/kg total) received 50 mg63 doses (6 vials) with a total
cost of $3,600. Taking into account the individual weight of
patients on this study, the average cost saving was approximately
U$2,307 dollars per patient in the lowATG arm compared to
sATG.
Discussion
ATG is a potent immune-depleting induction therapy that has
significantly reduced the rate of acute rejection in solid organ
transplantation. At the same time, however, high dose ATG is
associated with increased incidence of leukopenia, malignancy and
Table 1. Baseline characteristics of renal transplant recipients and donors.
sATG 3.75 mg/kg (n=23) lowATG 2.25 mg/kg (n=20) P Value
Recipients’ characteristics
Age at transplant (yr) 52.9612.1 56.6611.6 0.311
Body weight (kg) 78.5622.3 88.5 621.8 0.148
Body mass index (kg/m
2)2 7 . 6 64.8 29.165.9 0.364
PRA (%) 0 0
Pre-transplant diabetes (%) 11 (47.8) 9 (45) 0.874
Re-transplant (%) 2 (8.6) 1 (5.0) 0.499
Race/ethnicity (%) 0.246
White 13 (56.5) 16 (80)
Hispanic 6 (26.0) 2 (10)
African American 2 (8.7) 2 (10)
Other 2 (8.7) 0 (0)
Gender (%) 0.456
Males 16 (69.5) 16 (80)
Females 7 (30.4) 4 (20)
CKD etiology (%) 0.859
DM 11 (47.8) 9 (45)
HTN 1 (4.3) 3 (15)
GN 5 (21.7) 6 (30)
PKD 4 (17.3) 1 (5)
Other 2 (8.7) 1 (5)
Length of dialysis prior to transplant (months) 24.7623.9 31.2624.7 0.389
History of CAD 4 (17.4) 9 (45) 0.0591
Average follow up (months) 15.966.5 17.865.15 0.796
Donors’ characteristics (%) 0.392
Females 10 (43.5) 6 (30)
Males 13 (56.5) 14 (70)
Type of donors (%) 0.849
Deceased donor 14 (60.8) 12 (60)
Living donor 9 (39.2) 8 (40)
Extended-criteria donor 4 (17.4) 6 (30) 0.349
Donor age (yr) 44.4613.4 47.5613.5 0.468
CIT (min) 3786332 4336421 0.688
Kidney weight (grams) 213.4653.5 209.1651.0 0.809
CKD, chronic kidney disease; CAD, coronary artery disease; CIT, cold ischemia time; GN, glomerular nephritis, ECD, extended-criteria donor; PKD, polycystic kidney
disease; PRA, panel reactive antibody.
doi:10.1371/journal.pone.0104408.t001
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clinical use, its optimal dose is still controversial, in particular in
the setting of steroid withdrawal.
For the evaluation of efficacy and safety, multiple trials have
been conducted to optimize ATG dosage [18]. The initial trials
used relatively high cumulative doses of ATG of 10.5 mg/kg with
cyclosporine and low-dose steroids maintenance regimen [19,20],
followed by efforts to reduce the dosage of ATG. Recently
published observational study using ATG induction registry of
2,322 living donor kidney transplants from 49 different centers
reported that the mean cumulative dose was 5.29 mg/kg, with
93.6% rejection free survival at 5 years. The registry consisted of a
heterogeneous group of patients and the majority of them were
receiving low dose steroids long-term [21], leading to difficulties in
extrapolating the results to this specific subgroup of patients.
Another recent 10-year follow-up study using an early steroid
withdrawal reported the use of a total dose 6.25–7.5 mg/kg of
thymoglobulin [22]. Wong et al. compared different cumulative
dosages of thymoglobulin (3.0 mg/kg vs 4.5 mg/kg), and showed
no statistically significant difference in acute rejection rate and
graft function up to 24 months post transplantation [23]. Though
it was relatively small study (7 vs. 9 patients in each arm) and all
patients were continued on steroids, this encouraged us to further
reduce thymoglobulin dosage in our transplant program.
Our study showed that a lower dose of 2.25 mg/kg of ATG was
safe and effective in preventing acute rejection in combination
Figure 2. Graft function after transplantation. Serum creatinine was measured at 1, 6, 12 months post-transplantation, as a surrogate of graft
function. Means6SD. At each time point, there was no statistically significant difference in serum creatinine between low-dose and high-dose arms
by unpaired t-test analysis.
doi:10.1371/journal.pone.0104408.g002
Table 2. Outcomes and complications after kidney transplantation.
sATG 3.75 mg/kg (n=23) lowATG 2.25 mg/kg(n=20) P Value
Rejection 4 (17%) 2 (10%) 0.662
Leukopenia 10 (43%) 6 (30%) 0.342
Severe infection 3 (13%) 2 (10%) 0.556
BK nephropathy 1 (4%) 0 (0) 0.331
CMV infection 2 (8%) 0 (0) 0.487
Patient survival 23 (100%) 17 (85%) 0.106
Delayed graft function (DGF) 3 (14.3%) 8 (40%) 0.0508
sCre post-transplant (mg/dL)
1 month 1.5860.10 1.7760.13 0.267
6 months 1.3860.08 1.4160.10 0.853
12 months 1.3360.07 1.4060.10 0.563
Trough tacrolimus level (mean6SD; ng/mL)
3 months 7.2461.50 7.7862.56 0.421
6 months 7.6061.80 6.8161.99 0.237
12 months 7.2062.62 5.6764.05 0.204
Mycophenolate Mofetil dose (mean6SD; mg/day)
3 months 17306438 14336457 0.092
6 months 15356458 13846463 0.402
12 months 13546482 11816462 0.392
CMV, cytomegalovirus; sCre, serum creatinine.
doi:10.1371/journal.pone.0104408.t002
Low Dose ATG in Renal Transplant Recipients
PLOS ONE | www.plosone.org 5 August 2014 | Volume 9 | Issue 8 | e104408with early steroid withdrawal in our non-sensitized kidney
transplant cohort. This dose was about 1/3 of the commonly
used dose of ATG in most centers. Two cardiovascular deaths with
functioning grafts in the lowATG group were likely to have
occurred by chance despite randomization, and were unlikely
related to difference in ATG dose given. The barely significant
increase in CAD history in the low ATG group also supports this
hypothesis. In addition, we observed a non-significant reduction in
the incidence of leukopenia, CMV and BK infections in lowATG
arm, suggesting possible benefit from lower dose ATG. In
contrary, DGF was more common in the lowATG group
(p=0.05). Reviewing Table 1, we observe a non-significant trend
towards higher proportion of ECD kidneys and greater mean cold
ischemia time in the lowATG group (30% vs 17% and 433 vs
378 min, p.0.05). Since prior data from larger randomized trials
did not show lower DGF in ATG compared to other induction
therapies (18), it is hard to conclude the significance of these
findings in this smaller cohort. Despite that, the absence of
primary graft losses on both groups and the good renal function at
12 months are reassuring. Although this report is an exploratory
Figure 3. Flow cytometric analyses of peripheral T cells at different time points after transplantation. A, Representative gating strategy
of peripheral blood mononuclear cells with live gate, CD4 and CD8 subsets and effector memory T cells (CD45RO
+CD62Llow). B, Percentage of total
CD4 cells and total CD8 cells at 0, 3, 6 and 12 months after transplantation. C, Percentage of CD4
+ and CD8
+ effector memory cells after
transplantation. Data are expressed as mean and standard deviation (n=18-20 per group).
doi:10.1371/journal.pone.0104408.g003
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must be further validated in a larger trial. Since study conclusion,
Lahey Clinic has now adopted the lower dose ATG as standard of
care in non-sensitized transplant recipients.
Aside from ATG, other induction agents such as basiliximab
(anti-IL2 receptor mAb, Novartis) or alemtuzumab (anti-CD52
mAb, Berlex Laboratories) have been used in combination with
tacrolimus maintenance and steroid withdrawal. One of the largest
prospective trials on steroid withdrawal reported that the rejection
rate was higher with basiliximab compared to ATG (24.2% vs
14.4%), though long-term graft outcomes were similar [24].
Alemtuzumab has been tested on a recent randomized controlled
trial in patients undergoing steroid withdrawal and was found to
be associated with lower rates of acute rejection when compared to
basiliximab in low-risk recipients, though late rejections were more
common in the alemtuzumab group (1–3 years after transplant)
[25]. This is a concern since the follow-up of transplant recipients
tends to be less frequent after the first year of transplantation and a
rejection episode may go unnoticed for few months.
In face of the increased budget constraints that transplant
centers and hospitals are undergoing and the huge expense that
ATG accounts for, reduction of ATG dose could have an
important financial benefit and a possible cost-reduction of
,U$3,000/patient could be obtained by reducing the ATG dose
from our standard protocol (3.75 mg/kg total) to the study dose of
2.25 mg/kg total. Although basiliximab is less expensive (,$4,000
per patient) than ATG, it is a relatively less potent immunosup-
pressant and is associated with a higher rate of rejection in patients
that undergo steroid withdrawal [24]. Alemtuzumab costs less as
well ($1,689 for the recommended single dose of 30 mg) and
requires shorter hospital stay, given its use as a one-time dose at
the time of transplant. However, alemtuzumab is associated with
significantly more prolonged T cell depletion, which may require
years to recover [18,26]. In addition, Alemtuzumab may promote
the development of donor-specific antibodies through its signifi-
cant effect on B cells subsets [27]. Nevertheless, thymoglobulin and
alemtuzumab had similar patient and graft outcomes in recent
randomized trials [28,29]. In sum, ATG seems to be the preferred
induction agent for patients undergoing steroid withdrawal.
Immune reconstitution after administration of T-cell depletion
by thymoglobulin is also of great interest, in particular with
experimental evidence suggesting that it may promote tolerance
through the induction and expansion of Tregs [14,30]. In children,
thymopoiesis plays an important role in the reconstitution of T
cells after ATG depletion, while in adults, homeostatic prolifer-
ation is dominant due to the progressive atrophy of thymus with
age [30,31]. This homeostatic proliferation is predominantly an
IL-7 mediated process, enabling T-cell clone which survived
depletion to expand. Recent thymic emigrants (RTE) are a subset
of T cells that proliferates in response to IL-7 in the apparent
absence of other stimulation and may play an important role in the
lymphocyte reconstitution after T-cell depletion [17]. Our findings
suggest that both higher and lower dose ATG significantly reduce
the RTE subset and this subset remains lower than at baseline
even 12 months following transplantation, though there was a
trend towards greater reduction in the sATG group. This may
allude to some long-term consequences of ATG in the homeostasis
of T cell subsets and using a lower dose may have potential to limit
that. It is clear that immunosuppression has this cumulative effect
and once given, it is not possible to take it back and long-term
consequences in the immune system are seeing decades to come.
In face of our overall prolongation of survival, it is critical to
minimize the life-immunosuppression dose.
The limitations of our study include the small number of
patients, the predominance of Caucasians, the lack of blinding, the
absence of protocol biopsies and the exclusion of sensitized
Figure 4. Flow cytometric analyses of Tregs and recent thymic emigrants (RTE) CD4 cells at different time points after
transplantation. Representative contour plots of Tregs (A) (CD25
+Foxp3
+ of CD4
+ cells) and RTEs (D) (CD45RA
+CD31
+ of CD4
+ cells) cells after
gating on CD4
+ T cells at different time points after transplantation. Percentage of Tregs (B) and ratio of Tregs related to baseline (C) at different
points after transplantation. E, Percentage of RTEs at different points after transplantation. Data are expressed as mean and standard deviation
(n=18-20 per group).
doi:10.1371/journal.pone.0104408.g004
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elucidate the impact of ATG dose on the malignancy rate.
In conclusion, low-dose ATG (2.25 mg/kg) is a promising
option as an induction therapy in low-risk patients with no
significant differences in acute rejection or graft function when
compared to sATG (3.75 mg/kg), and with possibly less leukope-
nia and infectious complications. In addition, our peripheral blood
cell analyses showed similar T cell depletion efficiency with the
lower dose ATG. Larger studies are warranted to confirm these
findings.
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